(VERU) Veru - Ratings and Ratios

Veru Inc. (NASDAQ:VERU) is a late-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). The company has a diverse portfolio, including the FC2 female condom, which provides dual protection against unplanned pregnancy and sexually transmitted infections. Verus pipeline includes enobosarm, a selective androgen receptor modulator (SARM) being investigated for sarcopenic obesity and metastatic breast cancer, and sabizabulin, a microtubule disruptor aimed at treating hospitalized patients with viral lung infections at high risk for ARDS. Formerly known as The Female Health Company, Veru Inc. rebranded in 2017 to reflect its expanded focus on biopharmaceuticals. Incorporated in 1971, the company is headquartered in Miami, Florida.

Over the next three months, Veru Inc. is expected to experience sideways price action with potential upside driven by clinical trial developments. The stock is currently trading below its 20-day and 50-day moving averages, indicating bearish momentum. However, the companys focus on high-value therapeutic areas and its pipeline progress could attract investor interest. The relatively low average true range (ATR) suggests manageable volatility, while the forward P/E ratio of 117.65 reflects expectations for significant growth. The companys market cap of $75.58M and price-to-sales ratio of 4.48 indicate a speculative investment profile, with success heavily dependent on clinical outcomes and regulatory approvals.